We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.01%
This Fund
S&P 500
This Quarter Est. Return
+6.89%
1 Year Est. Return
+62.01%
3 Year Est. Return
+164.15%
5 Year Est. Return
+274.12%
10 Year Est. Return
+2,470.02%
AUM
$1.31B
AUM Growth
-$51.4M
Cap. Flow
-$54.7M
Cap. Flow %
-4.18%
Top 10 Hldgs %
12.11%
Holding
1,682
New
422
Increased
338
Reduced
347
Closed
506

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$18.2M
2
TER icon
Teradyne
TER
+$15.9M
3
BE icon
Bloom Energy
BE
+$15.3M
4
CYBR
CyberArk
CYBR
+$15.2M
5
EXAS
Exact Sciences
EXAS
+$13.4M

Sector Composition

Rank Sector Weight
1 Technology 22.29%
2 Healthcare 14.62%
3 Consumer Discretionary 10.89%
4 Industrials 8.81%
5 Communication Services 8.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARWR icon
326
Arrowhead Research
ARWR
$11.9B
$954K 0.07%
15,217
+1,710
+13% +$108K
BCS icon
327
Barclays
BCS
$92.7B
$952K 0.07%
45,000
CRM icon
328
Salesforce
CRM
$151B
$942K 0.07%
5,049
+1,090
+28% +$226K
PSTL
329
Postal Realty Trust
PSTL
$694M
$935K 0.07%
50,372
+15,461
+44% +$287K
TSLA icon
330
Tesla
TSLA
$1.23T
$933K 0.07%
2,510
-14,846
-86% -$6.12M
MLTX icon
331
MoonLake Immunotherapeutics
MLTX
$1.57B
$911K 0.07%
+48,883
New +$810K
USFR icon
332
WisdomTree Floating Rate Treasury Fund
USFR
$18.1B
$906K 0.07%
18,000
TIPT icon
333
Tiptree Inc
TIPT
$662M
$905K 0.07%
+53,459
New +$915K
BRK.B icon
334
Berkshire Hathaway Class B
BRK.B
$1.1T
$903K 0.07%
1,885
+1,255
+199% +$616K
FLGT icon
335
Fulgent Genetics
FLGT
$470M
$895K 0.07%
56,309
+18,813
+50% +$408K
BMY icon
336
Bristol-Myers Squibb
BMY
$133B
$884K 0.07%
14,578
-3,141
-18% -$183K
LIN icon
337
Linde
LIN
$221B
$881K 0.07%
1,777
-1,134
-39% -$535K
ENSG icon
338
The Ensign Group
ENSG
$10.4B
$879K 0.07%
4,364
-1,938
-31% -$379K
IQV icon
339
IQVIA
IQV
$38.7B
$876K 0.07%
5,138
-186
-3% -$36.3K
CACI icon
340
CACI
CACI
$11B
$875K 0.07%
1,608
-361
-18% -$217K
MHK icon
341
Mohawk Industries
MHK
$7.5B
$871K 0.07%
8,849
+2,959
+50% +$345K
TEAM icon
342
Atlassian
TEAM
$25.6B
$870K 0.07%
+12,744
New +$1.26M
INVE icon
343
Identive
INVE
$63.4M
$867K 0.07%
234,426
-297,525
-56% -$1M
SPY icon
344
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$857K 0.07%
1,318
+87
+7% +$59.2K
MASI
345
DELISTED
Masimo
MASI
$842K 0.06%
+4,732
New +$743K
SU icon
346
Suncor Energy
SU
$79.4B
$841K 0.06%
12,726
-2,774
-18% -$153K
ALAB icon
347
Astera Labs
ALAB
$53.3B
$832K 0.06%
7,591
+6,264
+472% +$892K
BKR icon
348
Baker Hughes
BKR
$60B
$831K 0.06%
13,605
+5,081
+60% +$294K
CVS icon
349
CVS Health
CVS
$133B
$827K 0.06%
11,518
+8,895
+339% +$685K
FLXS icon
350
Flexsteel Industries
FLXS
$302M
$827K 0.06%
+18,406
New +$853K

Similar funds

Prelude Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Prelude Capital Management held 1,682 positions worth $1.31B, down 3.8% from $1.36B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Prelude Capital Management withdrew a net $54.7M in Q1 2026, closing 506 positions and reducing 347 holdings. Its most notable exit was CyberArk, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Prelude Capital Management opened a new position in Appian worth $9.41M.

  • Prelude Capital Management's largest Q1 2026 buy was Appian: 390,321 shares worth $9.41M.
  • Prelude Capital Management added most to Penumbra in Q1 2026, an estimated $15.3M increase.
  • Prelude Capital Management's biggest Q1 2026 reduction was SPDR Gold Trust, cutting an estimated $18.2M.
  • Prelude Capital Management fully exited CyberArk in Q1 2026, selling an estimated $15.2M.
  • Prelude Capital Management's ten largest holdings make up 12% of its $1.31B portfolio in Q1 2026.
  • Prelude Capital Management opened 422 new positions and closed 506 in Q1 2026.
  • Prelude Capital Management's portfolio value fell 3.8% quarter-over-quarter to $1.31B.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.